Retired electrician Joe Walsh in December became the first Alzheimer’s patient to try a nasal spray used to treat other ...

The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

The drug is designed to reduce inflammation in the brain and has been used on MS, cancer and migraine headaches.

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...

Joe Walsh is now testing a new treatment using a nasal spray, the medication inside is called Foralumab. He is the first patient with Alzheimer's to try it. The Walsh family is hopeful. Foralumab is ...

The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...

Since using black market nasal tanning spray, Harper has had facial flushes, acne, and more freckles. The illegal spray can have serious side effects, according to the Therapeutic Goods ...

The Food and Drug Administration (FDA) approved Johnson & Johnson's ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...

This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other ...

PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment ...

The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.

On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...